0000950170-24-005561.txt : 20240118 0000950170-24-005561.hdr.sgml : 20240118 20240118200008 ACCESSION NUMBER: 0000950170-24-005561 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: van Dijk Marcus Antonius CENTRAL INDEX KEY: 0001881659 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 24543427 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 ownership.xml 4 X0508 4 2024-01-16 0001840229 MiNK Therapeutics, Inc. INKT 0001881659 van Dijk Marcus Antonius 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 false true false false Chief Scientific Officer false Stock Option 0.87 2024-01-16 4 A false 15000 0.00 A 2034-01-16 Common Stock 15000 15000 D Stock Option 0.87 2024-01-16 4 A false 171078 0.00 A 2034-01-16 Common Stock 171078 171078 D An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter. An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024. By: /s/ Christine Klaskin, Attorney-in-Fact for Marc Antonius van Dijk 2024-01-18